The price of Abiraterone, a crucial medication used in the treatment of prostate cancer, has seen a significant increase, raising alarm among patients and healthcare advocates. Recent reports indicate that the cost of the drug has surged by nearly 20% over the past year, putting additional financial strain on those already battling cancer.

Abiraterone, marketed under the brand name Zytiga, is essential for many patients as it helps inhibit tumor growth by reducing hormone levels. Advocates argue that the rising costs make it increasingly difficult for patients to afford necessary treatments, potentially impacting their health outcomes.

Health experts are calling for greater transparency in drug pricing and increased efforts to negotiate lower costs with pharmaceutical companies. As patients and families grapple with these rising expenses, the urgency for systemic change in the healthcare industry has never been more pronounced.